Risk of Progression and Survival in Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study

Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with re...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kumar, Shaji, Lee, Jae Hoon, Lahuerta, Juan J., Morgan, Gareth, Richardson, Paul G., Crowley, John, Haessler, Jeff, Feather, John, Hoering, Antje, Moreau, Philippe, LeLeu, Xavier, Hullin, Cyrille, Klein, Saskia K., Sonneveld, Pieter, Siegel, David, Bladé, Joan, Goldschmidt, Hartmut, Jagannath, Sundar, San Miguel, Jesus, Orlowski, Robert, Palumbo, Antonio, Sezer, Orhan, Durie, Brian G.M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4109061/
https://ncbi.nlm.nih.gov/pubmed/21799510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2011.196
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller